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Abstract
Biological agents which specifically block tumor necro-
sis factor (TNF) have been reported as useful in treat-
ing sarcoidsis. Over the past four years, many centers
in America have reported on the use of  one or more
anti-TNF agent. These are: the TNF receptor antago-
nist etanerecept, the chimeric monoclonal antibody
infliximab, and the humanized monoclonal antibody
adalimumab. Infliximab is given intravenously, while
etanerecept and adalimumab are given subcutaneous-
ly. In the reports to date, infliximab appears to be the
most effective in treating sarcoidosis. At the Universi-
ty of  Cincinnati, 122 treatment regimens have been
The treatment of  sarcoidosis varies widely
from no therapy to systemic corticosteroids
and other agents1. Alternatives to corticos-
teroids have been sought for patients requir-
ing chronic therapy or those patients requir-
ing high doses of  corticosteroids2. Among
the possible targets for therapy, the cytokine
tumor necrosis factor alpha (TNF) has been
the subject of  investigation3. This cytokine
is responsible for both the initiation and per-
petuation of  granulomatous response. Stud-
ies have shown increased levels of  TNF re-
leased by alveolar macrophages are seen in
active sarcoidosis patients. During corticos-
given with the various agents (13 with etanerecept, 27
with adalimumab, and 82 with infliximab). Of  the in-
fliximab treated patients, 58 (71%) improved, while
only 13 (48%) improve on adalimumab and 3 (23%)
on etanerecept. Clinical worsening of  the sarcoidosis
occurred in 5 (38%) of  the etanerecept and 10 (37%)
of  the adalimumab patients, while only 11 (13%) of
the infliximab patients (Chi square=15.80, p<0.005).
These observations suggest that there is a difference
in response to anti-TNF agents in treating sarcoidosis.
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teroid therapy, alveolar macrophages from
stable patients no longer release increased
TNF. However, alveolar macrophages from
patients with worsening disease despite cor-
ticosteroids release increased TNF4.
Several effective agents for treating sarcoido-
sis have been shown to suppress TNF re-
lease from alveolar macrophages during suc-
cessful therapy. These include prednisone5,
methotrexate5, and azathioprine6, The suc-
cess of  these agents has led to interest in
using more specific anti-TNF agents. Three
biological agents approved for use in the
United States block TNF. These include the
monoclonal antibodies infliximab and adali-
mumab and the TNF receptor antagonist
etanercept.
Infliximab was first reported as useful in
treating chronic sarcoidosis in 20017. Since
that time, more than 25 case reports and case
series have been published demonstrating
benefit for treating sarcoidosis. This includes
pulmonary7, cutaneous7, ocular8, and neuro-
logic manifestations9. These observations led
to two randomized trials of  infliximab. Both
of  these studies demonstrated benefit over
placebo in treating chronic pulmonary dis-
ease. The larger of  these studied a total of
138 patients and has been discussed by Dr.
Drent in this symposium. The study dem-
onstrated a significant improvement in the
vital capacity and chest roentgenogram with
24 weeks of  therapy10.
Etanercept has also been used in sarcoido-
sis. Utz et al treated 17 patients with acute
pulmonary sarcoidosis in an open label tri-
al11. They found no benefit and a third of
their patients’ worsened while on therapy. A
randomized trial of  etanercept versus place-
bo was performed on patients with chronic
ocular sarcoidosis12. All patients had active
disease despite at least six months of meth-
otrexate. There was no difference in the re-
sponse rate of  the etanercept patients com-
pared to placebo patients. In that study, a
third of  the etanercept treated patients had
worsening disease while on therapy. There
has been limited information regarding the
use of  adalimumab for sarcoidosis13.
In order to clarify the relative value of  the
three anti-TNF agents for sarcoidosis, we
compared our own experience. Table I sum-
marizes the number of  treatment regimens
given to chronic sarcoidosis patients seen at
the University of  Cincinnati Interstitial Lung
Disease and Sarcoidosis clinic. All patients
received at least two months of  therapy.
Some patients were treated with more than
one agent. The response to therapy was de-
termined based on a retrospective review of
Table I – Response Rate to anti-TNF therapy at University of Cincinnati Interstitial Lung Disease and Sarcoidosis Clinic
Drug Number of Patients Worsened* Stable Improved
Etanercept 13   5 (38.5%)   5 (38.5%)   3 (23.1%)
Adalimumab 27 10 (37.0%)   4 (14.8%) 13 (48.1%)
Infliximab 82 11 (13.4%) 13 (15.9%) 58 (70.7%)
Total 122
* Number (percent)
Different rates of response between groups, Chi square=15.80, p<0.005
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the chart. The patient was felt to be worse if
clinical status worsened or concomitant med-
ications had to be increased. The patient was
felt to have improved if  clinical status of  one
or more organ improved or concurrent med-
ications were reduced. Patients could also
remain stable on therapy. All three drugs
improved some of  the patients, with the larg-
est rate of  response for infliximab and the
lowest rate for etanercept. Etanercept and
adalimumab had similar rates of  worsening
during therapy. The rate of  response was sig-
nificantly different between the three groups
(Chi square=15.80, p<0.005). No major
complications were noted for the etanere-
cept treated patients. Five (18.5%) of  the
patients treated with adalimumab had com-
plications: reactions at injection sites (3 pa-
tients) and recurrent infections (2 patients).
Nineteen (23.2%) of the patients treated with
infliximab encountered complications: ana-
phylactic reactions (2 patients), hypotension
without anaphylaxis (2 patients), other aller-
gic reactions (5 patients), gastrointestinal
bleeding (3 patients), recurrent infections (4
patients), alopecia (1 patient), and skin can-
cers diagnosed during therapy (2 patients).
We did not encounter any cases of  tubercu-
losis reactivation during therapy.
These drugs work equally well in rheuma-
toid arthritis. However, there is a difference
in effectiveness is noted in Crohn’s disease,
with infliximab much more effective than
adalimumab, and etanerecept having very
limited activity3. Infliximab is also associat-
ed with a much higher risk for reactivation
for tuberculosis than etanerecept14. This dif-
ference could be due to several factors. One
is the different mechanisms of  action, with
etanercept acting as a receptor antagonist,
while the other agents are monoclonal anti-
bodies against TNF. There is also the poten-
tial dose effect, since the intravenous dosing
of  infliximab lead to high peak dose. This
could lead to better cellular penetration. It
has been proposed that transmembrane TNF
is important in initiating granulomatous re-
sponse, and that this is best blocked by in-
travenous infliximab15. In Crohn’s disease
patients, infliximab was found to bind cells
releasing TNF and this led to antibody de-
pendant cell lysis. This lysis was associated
with reduced inflammatory response. This
same lysis was not seen with etanerecept16.
These observations support the potential
role of  anti-TNF agents in treating sarcoido-
sis. Major questions remain, such as when to
use the agents and when to stop them. These
agents are costly both financially and in terms
of  toxicity. It is hoped that other anti-TNF
agents will become available for treating sar-
coidosis and that these new agents will have
less toxicity.
Reference List
1. Baughman RP, du Bois RM, Lower EE. Sarcoidosis.
Lancet. 2003;361:1111-8.
2. Baughman RP, Lower EE. Alternatives to corticosteroids
in the treatment of  sarcoidosis. Sarcoidosis. 1997;14:121-30.
3. Baughman RP, Iannuzzi M. Tumour necrosis factor in
sarcoidosis and its potential for targeted therapy. Bio-
Drugs. 2003;17:425-31.
4. Ziegenhagen, M. W., Rothe, E., Zissel, G., and Muller-
-Quernheim, J. Exagerated TNFalpha release of  alveo-
lar macrophages in corticosteroid resistent sarcoidosis.
Sarcoidosis Vasc.Diffuse.Lung Dis 19, 185-190. 2002.
Ref  Type: Generic
5. Baughman RP, Lower EE. The effect of  corticoste-
roid or methotrexate therapy on lung lymphocytes and
macrophages in sarcoidosis. Am Rev Respir Dis.
1990;142:1268-71.
6. Muller-Quernheim J., Kienast K, Held M, Pfeifer S,
Costabel U. Treatment of  chronic sarcoidosis with an
Tumor Necrosis Factor inhibition in treating sarcoidosis: the American Experience
Robert P Baughman
R E V I S T A  P O R T U G U E S A  D E  P N E U M O L O G I A
Vol XIII   Suplemento 2   Outubro 2007
S 50
azathioprine/prednisolone regimen. Eur Respir J.
1999;14:1117-22.
7. Baughman RP, Lower EE. Infliximab for refractory sar-
coidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:70-74.
8. Baughman RP, Bradley DA, Lower EE. Infliximab for
chronic ocular inflammation. Int J Clin Pharmacol Ther.
2005;43:7-11.
9. Doty JD, Mazur JE, Judson MA. Treatment of  sarcoi-
dosis with infliximab. Chest. 2005;127:1064-71.
10. Baughman RP, Drent M, Kavuru MS, Judson MA,
Costabel U, du Bois RM et al. Infliximab therapy in pati-
ents with chronic sarcoidosis and pulmonary involve-
ment. Am J Respir Crit Care Med. 2006;in press.
11. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-
-Pavlovic Z et al. Etanercept for the treatment of  stage
II and III progressive pulmonary sarcoidosis. Chest.
2003;124:177-85.
12. Baughman RP, Lower EE, Bradley DA, Raymond
LA, Kaufman A. Etanercept for refractory ocular sar-
Tumor Necrosis Factor inhibition in treating sarcoidosis: the American Experience
Robert P Baughman
coidosis: results of a double-blind randomized trial.
Chest. 2005;128:1062-7.
13. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez
L, Benticuaga MN. Treatment of  therapy-resistant sar-
coidosis with adalimumab. Clin Rheumatol. 2005;:1-
-2.:1-2.
14. Keane J, Gershon S, Wise RP, Mirabile-Leven E, Ka-
senica J, Schwieterman WD et al. Tuberculosis associa-
ted with infliximab, a tumor necrosis factor-alpha neu-
tralizing agent. N Engl J Med. 2001;345:1098-104.
15. Wallis RS, Ehlers S. Tumor necrosis factor and gra-
nuloma biology: explaining the differential infection risk
of  etanercept and infliximab. Semin Arthritis Rheum.
2005;34:34-8.
16. Van den Brande JM, Braat H, van den Brink GR,
Versteeg HH, Bauer CA, Hoedemaeker I et al. Inflixi-
mab but not etanercept induces apoptosis in lamina pro-
pria T-lymphocytes from patients with Crohn’s disease.
Gastroenterology. 2003;124:1774-85.
